- China’s economy recovers fast in post COVID-19 era.
- The China pharma market is expected to be the second largest with further growth of 230% by 2030.
- Funding environment remains positive for biotech in China, China stood out in the M&A market In-licensing is expected to dominate in cross border transactions in the next 3-5 years.
- Regulatory reform continues to foster innovation in China, and out licensing is expected to grow in the next 5 -10 years.
- Experienced cross border business development professionals are highly needed to facilitate the transactions.
Copyright ©2021 BCC. All rights reserved.